Please send a Surgical Pathology H-1 form to Immunopathology with this request. If ER studies are desired on previous surgical material, please contact the Immunopathology resident at #4514. Provide the patient's name, hospital number and surgical pathology specimen number. Estrogen Receptor (ER) expression status in breast carcinoma is an important prognostic and predictive biomarker according to recently published guidelines. ER status determination has become a part of the routine assessment of these tumors. About 60-70% of these tumors are ER positive, and this is associated with a more favorable prognosis than ER negative tumors. Immunohistochemical assessment of ER (as well as progesterone receptor) status has been recently documented to be superior to ligand binding assays in predicting response to hormonal manipulation in breast carcinoma. Immunohistochemical staining is performed on formalin-fixed, paraffin-embedded sections of tumor. An immunohistochemical (IHC) score is generated by the interpreting pathologist. A score of >2 has been used to define ER positivity.

88342 Estrogen Receptor 88342-26 Estrogen Receptor Professional Interpretation